Sanofi unveils plan to save French R&D site that Viehbacher wanted to discard

When Chris Viehbacher was running Sanofi ($SNY), he had a plan to cut costs in France, in part by shuttering an R&D site in Toulouse that he said was so bad it hadn't developed an important drug in 20 years. Viehbacher was fired in October, and now Sanofi plans to pay German company Evotec at least €250 million ($310 million) over 5 years to take over the operations there and see if it can shift drug discovery into a higher gear. Story from FierceBiotech | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.